Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America
Descripción del Articulo
Objectives: Venetoclax combinations are a new standard for patients with acute myeloid leukemia (AML). We aimed to evaluate the safety and efficacy of these combinations in a period of accelerated approval in Latin-America. Methods: This observational study evaluated adults with acute myeloid leukem...
| Autores: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | artículo |
| Fecha de Publicación: | 2022 |
| Institución: | Instituto Nacional de Enfermedades Neoplásicas |
| Repositorio: | INEN-Institucional |
| Lenguaje: | inglés |
| OAI Identifier: | oai:repositorio.inen.sld.pe:20.500.14703/337 |
| Enlace del recurso: | https: //doi.org/10.1080/16078454.2021.2024940 https://hdl.handle.net/20.500.14703/337 |
| Nivel de acceso: | acceso abierto |
| Materia: | Acute myeloid leukemia azacytidine BCL-2 inhibitor cytarabine venetoclax https://purl.org/pe-repo/ocde/ford#3.02.21 |
| id |
INEN_37dfa593ab77695bff8a81c13ed63072 |
|---|---|
| oai_identifier_str |
oai:repositorio.inen.sld.pe:20.500.14703/337 |
| network_acronym_str |
INEN |
| network_name_str |
INEN-Institucional |
| repository_id_str |
. |
| spelling |
PublicationGómez-De León, ADemichelis-Gómez, RPinedo-Rodríguez, AEnriquez-Vera, DFlores-Jiménez, JACeballos-López, AARodríguez-Mejorada, MHerrera Riojas, MAOvilla-Martínez, RBáez-Islas, PCota-Rangel, XNeme-Yunes, YInclán-Alarcón, SLópez-Flores, NJColunga-Pedraza, PRRodríguez-Zúñiga, ACGómez-Almaguer, D2025-01-02T14:42:50Z2025-01-02T14:42:50Z2022https: //doi.org/10.1080/16078454.2021.2024940https://hdl.handle.net/20.500.14703/337Hematology (United Kingdom)Objectives: Venetoclax combinations are a new standard for patients with acute myeloid leukemia (AML). We aimed to evaluate the safety and efficacy of these combinations in a period of accelerated approval in Latin-America. Methods: This observational study evaluated adults with acute myeloid leukemia who received venetoclax-based therapy in 11 public or private centers in Mexico and Peru for both newly diagnosed or relapsed and refractory AML. Results: Fifty patients were included28 with newly diagnosed (ND) AML and 22 with relapsed/refractory (RR) disease. ND patients were older (64 vs. 40 yearsp < 0.001) with a lower functional capacity (ECOG ≥2 64.3% vs 9%p < 0.001). Venetoclax was frequently combined with azacytidine (60%) and prophylactic azoles (82%) with a median maximum dose of 200 mg (range, 100–600 mg). Hematologic toxicities were common. Complete response rates including patients with incomplete hematopoietic recovery were 78.6% in ND and 45.5% in RR patients, with a median overall survival of 9.6 (95% CI 3.7–15.5) and 8 months (95% CI 4.8–11.2). Discussion: Our study showed a preferred use of venetoclax plus azacytidine over cyatrabine. Patients in the first-line setting were similar to those in the landmark studies, while most patients with relapsed disease had received prior intensive therapies. Responses were favorable, with a median survival in agreement to other reports, albeit shorter than that observed in the randomized phase-3 trials. Conclusion: Venetoclax-based therapy in AML was effective despite dose reductions and prophylactic antifungals in two middle-income countries outside of a clinical trial setting.application/pdfengTaylor and Francis Ltd.UKinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/4.0/Acute myeloid leukemiaazacytidineBCL-2 inhibitorcytarabinevenetoclaxhttps://purl.org/pe-repo/ocde/ford#3.02.21Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-Americainfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionreponame:INEN-Institucionalinstname:Instituto Nacional de Enfermedades Neoplásicasinstacron:INENORIGINALVenetoclax-based combinations for acute myeloid leukemia optimizing their use in Latin-America.pdfapplication/pdf1769800https://repositorio.inen.sld.pe/backend/api/core/bitstreams/f7dc5bed-7f21-4718-a983-ef78284a34a0/downloadb67e2bcdc70851ec4da581ac5c6fc761MD51trueAnonymousREADTEXTVenetoclax-based combinations for acute myeloid leukemia optimizing their use in Latin-America.pdf.txtWritten by FormatFilter org.dspace.app.mediafilter.TikaTextExtractionFilter on 2025-08-22T08:04:21Z (GMT).Extracted texttext/plain45725https://repositorio.inen.sld.pe/backend/api/core/bitstreams/afee410a-3439-42bf-b56c-9e431d49e677/download3ef79e0dea63ebaf9f3544941ac2b703MD52falseAnonymousREADTHUMBNAILVenetoclax-based combinations for acute myeloid leukemia optimizing their use in Latin-America.pdf.jpgWritten by FormatFilter org.dspace.app.mediafilter.PDFBoxThumbnail on 2025-08-22T08:04:23Z (GMT).Generated Thumbnailimage/jpeg34591https://repositorio.inen.sld.pe/backend/api/core/bitstreams/edb11290-e8b7-458f-9d36-2ce6d36d9331/download94a6dafa89ba4e3e479f7c0051a96f0aMD53falseAnonymousREAD20.500.14703/337oai:repositorio.inen.sld.pe:20.500.14703/3372026-02-15T18:06:21.957Zhttps://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessopen.accesshttps://repositorio.inen.sld.peRepositorio del Instituto Nacional de Enfermedades Neoplásicasrepositorio@inen.sld.pe |
| dc.title.none.fl_str_mv |
Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America |
| title |
Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America |
| spellingShingle |
Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America Gómez-De León, A Acute myeloid leukemia azacytidine BCL-2 inhibitor cytarabine venetoclax https://purl.org/pe-repo/ocde/ford#3.02.21 |
| title_short |
Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America |
| title_full |
Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America |
| title_fullStr |
Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America |
| title_full_unstemmed |
Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America |
| title_sort |
Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America |
| author |
Gómez-De León, A |
| author_facet |
Gómez-De León, A Demichelis-Gómez, R Pinedo-Rodríguez, A Enriquez-Vera, D Flores-Jiménez, JA Ceballos-López, AA Rodríguez-Mejorada, M Herrera Riojas, MA Ovilla-Martínez, R Báez-Islas, P Cota-Rangel, X Neme-Yunes, Y Inclán-Alarcón, S López-Flores, NJ Colunga-Pedraza, PR Rodríguez-Zúñiga, AC Gómez-Almaguer, D |
| author_role |
author |
| author2 |
Demichelis-Gómez, R Pinedo-Rodríguez, A Enriquez-Vera, D Flores-Jiménez, JA Ceballos-López, AA Rodríguez-Mejorada, M Herrera Riojas, MA Ovilla-Martínez, R Báez-Islas, P Cota-Rangel, X Neme-Yunes, Y Inclán-Alarcón, S López-Flores, NJ Colunga-Pedraza, PR Rodríguez-Zúñiga, AC Gómez-Almaguer, D |
| author2_role |
author author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Gómez-De León, A Demichelis-Gómez, R Pinedo-Rodríguez, A Enriquez-Vera, D Flores-Jiménez, JA Ceballos-López, AA Rodríguez-Mejorada, M Herrera Riojas, MA Ovilla-Martínez, R Báez-Islas, P Cota-Rangel, X Neme-Yunes, Y Inclán-Alarcón, S López-Flores, NJ Colunga-Pedraza, PR Rodríguez-Zúñiga, AC Gómez-Almaguer, D |
| dc.subject.none.fl_str_mv |
Acute myeloid leukemia azacytidine BCL-2 inhibitor cytarabine venetoclax |
| topic |
Acute myeloid leukemia azacytidine BCL-2 inhibitor cytarabine venetoclax https://purl.org/pe-repo/ocde/ford#3.02.21 |
| dc.subject.ocde.none.fl_str_mv |
https://purl.org/pe-repo/ocde/ford#3.02.21 |
| description |
Objectives: Venetoclax combinations are a new standard for patients with acute myeloid leukemia (AML). We aimed to evaluate the safety and efficacy of these combinations in a period of accelerated approval in Latin-America. Methods: This observational study evaluated adults with acute myeloid leukemia who received venetoclax-based therapy in 11 public or private centers in Mexico and Peru for both newly diagnosed or relapsed and refractory AML. Results: Fifty patients were included |
| publishDate |
2022 |
| dc.date.accessioned.none.fl_str_mv |
2025-01-02T14:42:50Z |
| dc.date.available.none.fl_str_mv |
2025-01-02T14:42:50Z |
| dc.date.issued.fl_str_mv |
2022 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.version.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.doi.none.fl_str_mv |
https: //doi.org/10.1080/16078454.2021.2024940 |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.14703/337 |
| dc.identifier.journal.none.fl_str_mv |
Hematology (United Kingdom) |
| url |
https: //doi.org/10.1080/16078454.2021.2024940 https://hdl.handle.net/20.500.14703/337 |
| identifier_str_mv |
Hematology (United Kingdom) |
| dc.language.iso.none.fl_str_mv |
eng |
| language |
eng |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.uri.none.fl_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Taylor and Francis Ltd. |
| dc.publisher.country.none.fl_str_mv |
UK |
| publisher.none.fl_str_mv |
Taylor and Francis Ltd. |
| dc.source.none.fl_str_mv |
reponame:INEN-Institucional instname:Instituto Nacional de Enfermedades Neoplásicas instacron:INEN |
| instname_str |
Instituto Nacional de Enfermedades Neoplásicas |
| instacron_str |
INEN |
| institution |
INEN |
| reponame_str |
INEN-Institucional |
| collection |
INEN-Institucional |
| bitstream.url.fl_str_mv |
https://repositorio.inen.sld.pe/backend/api/core/bitstreams/f7dc5bed-7f21-4718-a983-ef78284a34a0/download https://repositorio.inen.sld.pe/backend/api/core/bitstreams/afee410a-3439-42bf-b56c-9e431d49e677/download https://repositorio.inen.sld.pe/backend/api/core/bitstreams/edb11290-e8b7-458f-9d36-2ce6d36d9331/download |
| bitstream.checksum.fl_str_mv |
b67e2bcdc70851ec4da581ac5c6fc761 3ef79e0dea63ebaf9f3544941ac2b703 94a6dafa89ba4e3e479f7c0051a96f0a |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio del Instituto Nacional de Enfermedades Neoplásicas |
| repository.mail.fl_str_mv |
repositorio@inen.sld.pe |
| _version_ |
1868438556399108096 |
| score |
12.821158 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
